NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan

NCT07465679

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Heart Failure With Reduced Ejection Fraction

Countries: Romania

The aim of this study was to describe the real-world clinical profile, treatment patterns, and guideline alignment of patients with heart failure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan in routine clinical practice in Romania. The study used secondary use of data, with all analyses conducted on anonymized, pre-existing data collected for routine clinical and administrative purposes.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria:

* A recorded diagnosis of HFrEF.
* At least one prescription of sacubitril/valsartan during the identification period.
* Age ≥18 years at the index date.

Exclusion criteria:

• Patients who do not meet inclusion criteria.

Locations (1)

Bucharest, Romania